NeuroMetrix, Inc. Announces Date for First Quarter 2021 Financial Results Conference Call
NeuroMetrix plans to release its 2021 Q1 financial results on April 22, 2021, before market opening. A conference call is scheduled for 8:00 a.m. Eastern Time on the same day to discuss these results and related business developments. Interested parties in the U.S. can join by calling 844-787-0799 with confirmation code 9554608, while international participants can use 661-378-9630. The earnings press release will be accessible on the Company’s website under the 'Investor Relations' tab.
- None.
- None.
WOBURN, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2021 first quarter financial results before the opening of the market on April 22, 2021. The Company will host a conference call at 8:00 a.m., Eastern Time on April 22, 2021 to discuss its financial results as well as business developments affecting the Company.
The conference call may be accessed in the United States by dialing 844-787-0799 and using the confirmation code 9554608. Internationally, the conference call may be accessed by dialing 661-378-9630 and using the same confirmation code. The earnings press release and accompanying condensed financial statements will be accessible from the Company's website at www.NeuroMetrix.com under the "Investor Relations" tab.
A replay of the conference call will be available starting two hours after the call by dialing 855-859-2056, domestically and 404-537-3406, internationally. The confirmation code to access the replay is 9554608. The replay will be available for one week after the conference call.
About NeuroMetrix
NeuroMetrix is an innovation-driven company focused on the development and global commercialization of non-invasive medical devices for the diagnosis and treatment of disorders involving the nervous system. The Company has three commercial products. DPNCheck® is a diagnostic device that provides rapid, point-of-care detection of peripheral neuropathies. ADVANCE® is a diagnostic device that provides automated, in-office nerve conduction studies for the evaluation of focal neuropathies. Quell® is a wearable neurostimulation device indicated for symptomatic relief of chronic pain that is available over-the-counter. For more information, visit www.NeuroMetrix.com.
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
neurometrix.ir@neurometrix.com
Source: NeuroMetrix, Inc.
FAQ
When will NeuroMetrix release its Q1 financial results?
What time is the NeuroMetrix conference call?
How can I access the NeuroMetrix earnings press release?
What is the confirmation code for the NeuroMetrix conference call?
